Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,803 total articles
vTv Therapeutics (VTVT) is a small-cap clinical-stage company with a potential first-in-class oral adjunct to insulin for Type 1 diabetes. Market cap is only $155M and the stock is trading close to $38. A positive CATT1 Phase 3 readout could re-rate the equity materially. This trade idea lays out an actionable long with entry, stop, and target for …
LSB Industries (LXU) looks like a classic mid-cap chemical story: improving cash flow, a clean current balance sheet, and corporate actions aimed at protecting large tax attributes. That combination creates a near-term trade setup with asymmetric upside if markets re-rate the company's NOLs and operational momentum. Entry $11.63, stop $9.50, target…
Sezzle (SEZL) sold off sharply to $73 after yesterday's action, creating a tactical entry into a company showing 67% revenue growth, best-in-class margins and a $2.5B market cap. This is a swing trade into near-term earnings with a defined stop and upside targets that reflect both technical support and fundamental optionality from new product launc…
Alphabet shares are set to run higher as Google Cloud scales into profitability and Ads stability holds. Valuation is elevated but supported by strong free cash flow, healthy margins and a fortress balance sheet. We reiterate Buy with a clear trade plan for a mid-term swing.
IBDRY has retraced to a technical support cluster near its 10-day and 9-day EMA; a clearer revenue cadence from contracted network fees and renewable PPAs reduces downside risk. We lay out a swing trade with entry, stop and target, and explain catalysts that could validate the trade or invalidate it.
<p>Terex (TEX) is executing a quieter but material strategic shift: Environmental Solutions and after-market/service growth are offsetting cyclical pressure in legacy materials processing and aerials. That mix shift is showing up in free cash flow, dividend consistency, and multiple compression room versus peers, creating a practical swing trade op…
HubSpot (HUBS) has been punished with the rest of the software sector, but fundamentals - a $700M+ free cash flow run-rate, an EV roughly equal to market cap, and a reasonable P/FCF - argue the downside is limited from today's levels. This trade idea outlines a mid-term long with a $265 entry, $240 stop and $350 target, driven by potential sector m…
Vaalco (EGY) looks like a beaten-up small-cap upstream that is beginning to stabilize. Portfolio simplification, a resilient dividend, cheap valuation multiples and constructive technicals argue that the worst operational and market pressure is behind the stock. We present a mid-term trade plan that captures upside from drilling catalysts and balan…
Golar LNG is trading near 52-week highs after locking multi-decade charters and building an ~ $13.7B EBITDA backlog. The market has largely priced the base — the known contracts and backlog - but has not fully rewarded optional upside from additional project wins, cost discipline, or successful redeployment. This trade idea takes a measured long wi…
Ashland (ASH) has outperformed off its 2025 low and is trading near $62.40. Fundamentals are mixed but cash generation ($154m FCF in last reported period), a manageable balance sheet and recurring dividend paint a constructive setup. We prefer buying a measured pullback with a stop beneath recent intraday lows and a mid-term horizon to capture a re…
MLSPF has pulled back to $7.91 after a sharp post-results sell-off. Technicals show the stock beneath its 10/20/50-day moving averages, but short-interest and short-volume data point to a crowded short trade and elevated bid for a rebound. We propose a tactical long with a mid-term horizon to capture mean reversion toward the $9.50 area, while prot…
Chord Energy is trading like a cyclical aftershock while fundamentals show cash generation, conservative balance sheet and bargain valuation multiples. This trade idea targets a mid-term rebound on valuation rerating with clearly defined entry, stop and target levels.
Match Group (MTCH) is trading well below its 52-week high after recent negative headlines and churn concerns. The business still generates near-$1B free cash flow, trades at a reasonable PE (~13.5), and sits on a healthy liquidity profile. Market reaction has overshot; we recommend a mid-term long with defined entry, stop, and target levels and cle…
Microsoft's mix of high-margin enterprise software, a dominant cloud platform and accelerating AI productization supports a premium valuation. With real-time market quotes not available here, the trade below uses a conservative entry and defined risk controls to capture further multiple expansion while protecting capital.
Adobe has been punished on fears that agentic GenAI will hollow out software licensing. The sell-off paints a better entry: strong cash generation, reasonable valuation, and improving technicals argue for a mid-term long. Trade plan, catalysts, and risk controls included.
International Tower Hill Mines (THM) trades like a levered call on the price of gold. With a market cap around $918M and 259.7M shares outstanding, a relatively small per-share move (about $0.443) equates to roughly $115M of market-cap change. Technical momentum is strong, liquidity is adequate and the stock still sits well below its 52-week high, …
G-III Apparel (GIII) is trading near the middle of its 52-week range but offers unusually strong free cash flow, a low debt load, recent dividend initiation and continued buybacks. These fundamentals plus an improving technical setup support a long trade with a clear entry, stop and target for a 180-trading-day time frame.
Harmony Gold (HMY) trades near $22.78 after a strong metals rally. The company’s gold operations generate meaningful cash flow today while management nudges a copper footprint into view. With a $14.6B market cap, a PE of 17.7 and bullish technicals, HMY offers a medium-risk swing opportunity to capture further upside as gold remains elevated and th…
Allstate is trading cheaply relative to earnings and cash flow after a period of investor concern about margin cyclicality. The business generates nearly $10B of free cash flow, carries modest leverage and trades at a mid-single-digit PE. This trade idea targets a mid-term rebound as P&C margin fears cool and above-average cash returns reassert val…
Match Group is trading below pre-2025 highs on steady free cash flow and a reasonable P/E. At $31.60 the stock offers a low-double-digit upside to a sensible re-rating target and a base dividend yield with potential for a larger capital-return program. This trade idea lays out an entry at $31.60, a $38 target and a $28 stop, with a 180-trading-day …
Boeing looks positioned to accelerate commercial airplane production after signs of renewed order momentum and a favorable industry backdrop. The share base is digesting mixed fundamentals and a high headline valuation, but near-term technicals and order flow create a tradable swing setup. We outline an entry, stop and target with catalysts and a b…
LeMaitre Vascular is a high‑margin, consistently growing specialist in peripheral vascular devices. Recent tempo of innovation, 70% gross margins in Q2 2025 and improving free cash flow make the business a compounding story. The stock has run hard into a 52‑week high but pulled back intraday; this trade idea buys the dip with tight risk controls an…
Visa is trading below its recent moving averages but remains a capital-light, high-margin global payments franchise with strong free cash flow ($22.9B) and a market cap near $605B. This trade idea lays out an entry at $317.54, a stop at $295.00, and a primary target of $360.00 over a 180 trading day horizon, with catalysts, valuation framing, and b…
Swatch Group is an underappreciated play on luxury resilience, brand diversification and margin recovery. We upgrade to Buy and lay out an actionable trade with a $240 entry, $300 target and $200 stop, supported by four concrete catalysts and a balanced risk plan.
TG Therapeutics (TGTX) is a 'Strong Buy' at current levels. BRIUMVI's rapid commercial traction, upgraded 2025 guidance and improving technicals justify a long trade into a 180-day horizon. The plan balances upside to the drug's share gains against execution and regulatory risks with a disciplined stop.
